U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870694) titled 'To Evaluate HU-045 With Moderate to Severe Glabellar Lines' on Oct. 06.
Brief Summary: A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin(R) in Patients With Moderate to Severe Glabellar Lines
Study Start Date: Sept. 03
Study Type: INTERVENTIONAL
Condition:
Glabellar Lines
Intervention:
DRUG: HU-045
HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted wi...